Two Sigma Advisers LP Has $30.31 Million Stake in Merus (NASDAQ:MRUS)

Two Sigma Advisers LP decreased its holdings in Merus (NASDAQ:MRUS - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 720,800 shares of the biotechnology company's stock after selling 9,000 shares during the quarter. Two Sigma Advisers LP owned 1.05% of Merus worth $30,310,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. State of Wyoming acquired a new position in Merus during the 4th quarter valued at about $48,000. Stempoint Capital LP boosted its holdings in shares of Merus by 46.0% in the fourth quarter. Stempoint Capital LP now owns 614,812 shares of the biotechnology company's stock valued at $25,853,000 after acquiring an additional 193,590 shares in the last quarter. Polar Asset Management Partners Inc. bought a new position in shares of Merus in the fourth quarter valued at approximately $1,318,000. Polar Capital Holdings Plc increased its stake in shares of Merus by 34.7% during the fourth quarter. Polar Capital Holdings Plc now owns 1,706,238 shares of the biotechnology company's stock valued at $71,747,000 after acquiring an additional 439,186 shares during the period. Finally, Parkman Healthcare Partners LLC raised its holdings in Merus by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company's stock worth $1,921,000 after purchasing an additional 331 shares in the last quarter. Institutional investors own 96.14% of the company's stock.

Merus Trading Up 32.5%

Shares of MRUS traded up $13.54 during midday trading on Monday, hitting $55.14. The stock had a trading volume of 7,872,333 shares, compared to its average volume of 733,508. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $61.28. The business has a 50-day simple moving average of $42.72 and a two-hundred day simple moving average of $43.41. The firm has a market cap of $3.82 billion, a P/E ratio of -13.96 and a beta of 0.94.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.23). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $26.49 million during the quarter, compared to analysts' expectations of $7.82 million. On average, analysts expect that Merus will post -3.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on MRUS shares. Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 price target on shares of Merus in a research note on Monday, May 19th. HC Wainwright reaffirmed a "buy" rating and set a $85.00 target price on shares of Merus in a research note on Monday, March 3rd. BMO Capital Markets set a $110.00 target price on Merus and gave the stock an "outperform" rating in a report on Friday. Guggenheim reissued a "buy" rating and issued a $109.00 price target on shares of Merus in a report on Friday, March 28th. Finally, Bank of America reduced their price objective on shares of Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Fourteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $86.00.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.